Vaccines targeting mutant KRAS to prevent pancreatic cancer
Official title: Mutant KRAS targeted vaccines for the interception of pancreatic cancer development
Funded at Johns Hopkins University · NIH-10940953 · Data updated 2026-11-12
This study is testing a new vaccine that helps the immune system fight pancreatic cancer by targeting specific gene changes, and it's for people at high risk of developing this cancer or those who have already had it removed.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $659,090 |
| NIH project number | 1R37CA292056-01 |
| Project ID | NIH-10940953 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with a family history of pancreatic cancer or those who have specific genetic mutations associated with increased cancer risk.
✕Less likely to help
Patients with advanced pancreatic cancer who are already symptomatic or have metastatic disease may not benefit from this research.
What this research studies
This research focuses on developing vaccines that target specific mutations in the KRAS gene, which are commonly associated with pancreatic cancer. By identifying individuals at high risk for pancreatic ductal adenocarcinoma (PDAC) and utilizing genetic testing and imaging techniques, the study aims to intercept the progression of cancer from premalignant lesions. The vaccine is designed to stimulate the immune system, particularly CD4 T cells, to recognize and attack cells with these mutations, potentially halting the development of cancer. Patients who have had resected PDAC may also benefit from this approach, as it aims to improve disease-free survival.
Why it matters
Potential benefit: If successful, this research could significantly reduce the incidence of pancreatic cancer by preventing its progression in high-risk individuals.
How similar studies have gone: Previous research has shown promising results with similar vaccine approaches in animal models, indicating potential for success in human applications.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Zaidi, Neeha — Johns Hopkins University
- Study coordinator: Zaidi, Neeha
Related research
Other NIH-funded projects on the same topics.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
-
Exosome-based microRNA biomarkers for early detection of pancreatic cancer
A patient-friendly look at a study using tiny blood-based RNA markers inside exosomes to catch pancreatic cancer early without invasive procedures.
-
Programmable implanted living materials to fight pancreatic cancer
A patient-facing program will explore a safe, implantable living material that delivers sequential immunotherapies directly to pancreatic tumors to help fight cancer.
-
Targeting how platelets and pancreatic cancer talk to each other
A study exploring whether blocking the interaction between platelets and pancreatic cancer cells could slow cancer growth and spread and help identify new biomarkers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.